Medtech deal value surged to $92.8 billion in 2025, the highest level in more than a decade, driven by three mega-deals. Yet overall activity lagged historical norms, with only 46 announced deals through November 30. This imbalance reflects the complex environment facing medtech deal makers. Despite strong balance sheets and fundamental performance, acquirers largely moved with caution amid regulatory shifts, macroeconomic pressure, and evolving investor expectations. However, several potentially transformative acquisitions in the second half signaled the potential for an increase in M&A activity.
Read the full article: PwC US Deals 2026 Outlook: Medtech //
Source: https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html